IRCT20090117001556N152尚未招募2 期
Rosiglitazone as an adjunctive therapy in the treatment of patients with moderate to severe major depressive disorder: A randomized double-blind placebo-controlled clinical trial
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Diagnosed with major depressive disorder (MDD) based on DSM5
- •Depression severity should be above 22 according to the Hamilton Depression Scale
- •Age between 18-60
排除标准
- •Psychotic patients
- •Diagnosis of any disturbances in other axes
- •The use of psychoactive drugs
- •The use of antidepressants in the last one month or ECT in the last two months
- •History of cardiovascular disease (EKG can be taken, and if there is a problem in the function of heart, the patient is excluded from the study)
- •Thyroid problems
- •Pregnant and lactating women
研究者
相似试验
尚未招募
2 期
The effect of Rosiglitazone on negative symptoms in schizophreniaSchizophreniaIRCT20090117001556N159niversity of social welfare and rehabilitation sciences50
尚未招募
2 期
The effect of rosiglitazone in the treatment of autismAutistic disorder.Autistic disorderF84.0IRCT20090117001556N150Tehran University of Medical Sciences50
已完成
不适用
Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?Diabetes mellitus type II (DM type II)Nutritional, Metabolic, EndocrineDiabetes mellitusISRCTN52245496Academic Medical Centre (AMC) (The Netherlands)22
暂停
不适用
Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?NL-OMON27919Academic Medical Center - Amsterdam22
已完成
3 期
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery DiseaseGlucose IntoleranceInsulin ResistancePrediabetesCoronary Artery DiseaseNCT01574820National Cheng-Kung University Hospital105